Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
COLL Stock Chart & Stats
$35.44
$3.70(12.70%)
At close: 4:00 PM EST
$35.44
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$23.23 - $50.79
Previous CloseN/A
Volume233.62K
Average Volume (3M)501.99K
Market Cap
$1.13B
Enterprise Value$1.81B
Total Cash (Recent Filing)$406.53M
Total Debt (Recent Filing)$940.56M
Price to Earnings (P/E)21.6
Beta0.40
Next Earnings
May 07, 2026EPS Estimate
1.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.04
Shares Outstanding31,753,210
10 Day Avg. Volume651,033
30 Day Avg. Volume501,986
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market Cap1.61
Enterprise Value/Revenue2.32
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda3.03
Forecast
1Y Price Target
$54.17Price Target Upside52.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)8.15
Revenue Forecast (FY)$809.89M
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyAcquisition of AZSTARYS expands the ADHD product lineup and, backed by patent protection, strengthens Collegium Pharmaceutical's long-term revenue durability and visibility.
Financial FlexibilityA strengthened balance sheet and a large syndicated credit facility increase capacity for accretive acquisitions and rapid business development, supporting growth initiatives and capital deployment.
Product DifferentiationAZSTARYS' combined immediate-release and long-acting formulation and complementary dosing profile with Jornay PM enable the company to address diverse patient needs and capture share primarily from generics rather than from internal products.
Bears Say
Authorized Generics CompetitionLaunches and plans for authorized generics for Nucynta IR and Nucynta ER intensify competitive pressure on the pain franchise and could reduce sales and margin contribution from those products.
Deal Valuation RiskThe deal valuation appears elevated, creating execution risk if AZSTARYS sales growth does not materialize enough to justify the premium paid.
Reliance On Business DevelopmentIncreased pressure on the pain portfolio heightens the importance of successful business development to replace revenue lost to generic erosion, exposing the company to acquisition execution and integration risk.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $23.23 and its highest was $50.79 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $1.13B.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Feb 26, 2026. The company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.139 by -$0.099.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.79.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 31,753,210 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $2.04 in its last earnings report, missing expectations of $2.139. Following the earnings report the stock price went down -3.344%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.17 (52.85% Upside)
$54.17 (52.85% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 48.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.40%
12-Months-Change
Fundamentals
Return on Equity
24.11%
Trailing 12-Months
Asset Growth
1.35%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong, broad-based commercial performance (notably Jornay PM) and robust financial outcomes for 2025 — record revenue, record adjusted EBITDA, strong cash generation, and materially improved leverage. Management reiterated disciplined capital deployment, added liquidity via a $980M syndicated facility, and expects Jornay to be a key growth driver in 2026 (guiding Jarday revenue +~31% YoY). However, near-term headwinds and risks include substantial increases in operating expenses due to commercialization investments, elevated gross-to-net rates (≈64%), expected seasonal Q1 pressure, a Q4 decline in Xtampza, and the impact of an authorized generic for Nucynta (partially mitigated by profit share). Overall, the positives (revenue growth, cash flow, leverage improvement, Jornay momentum, strategic financing) materially outweigh the lowlights, which are largely investment- and seasonality-driven.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$54.17
▲(52.85% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
Currently, No data available
---